Search Results
Your search for ,jCo matches 1778 pages
Showing 1651 - 1700Renal Cell Carcinoma Onset at ≤ 46 Years Could Serve as Marker for Genetic Testing
Approximately 5% to 8% of renal cell carcinoma cases are hereditary, and there are no guidelines for patient selection for germline mutation testing in this disease. In a study reported in the Journal of Clinical Oncology, Shuch et al from the National Cancer Institute assessed whether age at onset ...
Matched-Pairs Analysis Shows Better Survival With Allogeneic Transplantation vs Conventional Chemotherapy in Postremission Therapy for AML
In a prospective matched-pairs analysis reported in the Journal of Clinical Oncology, Stelljes et al in the German AML Cooperative Group compared outcomes with allogeneic stem cell transplantation vs conventional postremission chemotherapy in patients aged < 60 years with acute myeloid leukemia...
No Survival Difference for Autologous vs Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Chemotherapy-Sensitive Mantle Cell Lymphoma
In an analysis reported in the Journal of Clinical Oncology, Fenske et al compared outcomes with early or late autologous vs reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in a population of patients with chemotherapy-sensitive mantle cell lymphoma. They found no...
Phase II Pilot Study Does Not Support Phase III Investigation of IV High-Dose Interferon Without Maintenance in Resected Melanoma
There is evidence that high-dose interferon alfa-2b consisting of 4 weeks of daily intravenous interferon alfa-2b followed by 48 weeks of subcutaneous maintenance interferon alfa-2b three times per week reduces risk of recurrence of resected melanoma and that response may depend on the early...
Study Evaluates Risk of Depression by Race and Sex Among Patients With Newly Diagnosed Lung Cancer
In a study reported in the Journal of Clinical Oncology, Traeger et al evaluated risk of depression symptoms and psychosocial service use by race and sex among patients with newly diagnosed lung cancer. The investigators found that black men have the highest prevalence of depressive symptoms, white ...
No Difference for Aprepitant vs Dexamethasone for Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer
In a phase III study reported in the Journal of Clinical Oncology, Roila et al compared aprepitant vs dexamethasone in prevention of delayed emesis in breast cancer patients treated with anthracycline/cyclophosphamide who had received palonosetron/aprepitant/dexamethasone prophylaxis for acute...
Sustained Complete Responses With Novel Immunotherapy in Lymphoma
Approximately 40% of patients with Hodgkin or non-Hodgkin lymphoma have tumor cells that express the type II latency Epstein-Barr virus (EBV) antigens latent membrane protein 1 (LMP1) and LMP2. T cells specific for these antigens are present in low levels and may be rendered nonreactive by the...
No Overall Survival Benefit With Addition of Sunitinib to Prednisone in Metastatic Castration-Resistant Prostate Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Michaelson et al assessed the addition of the antiangiogenesis agent sunitinib (Sutent) to prednisone in patients with progressive metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. No...
Suboptimal Adverse Event Reporting in Cancer Clinical Trial Publications
In a study reported in the Journal of Clinical Oncology, Sivendran et al assessed the degree to which publication of phase III trials in oncology conformed with CONSORT (Consolidated Standards of Reporting Trials) recommendations for reporting adverse events. They found that adverse event...
No Benefit of Calcium/Magnesium in Preventing Oxaliplatin-Induced Sensory Neurotoxicity in Patients With Colon Cancer
In a phase III N08CB/Alliance trial reported in the Journal of Clinical Oncology, Loprinzi et al assessed whether calcium and magnesium treatment reduced oxaliplatin-related neurotoxicity in patients with colon cancer receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin). They found ...
Survival Benefit With High-Dose Cytarabine Induction in AML Patients Aged < 46 Years
In a European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) phase III trial (AML-12) reported in Journal of Clinical Oncology, Willemze et al compared induction regimens containing high-dose or standard-dose...
Increased Cardiovascular Risk Despite Healthier Lifestyle Characteristics in Hematopoietic Cell Transplant Survivors
In a study reported in the Journal of Clinical Oncology, Chow et al compared cardiovascular risk and risk factors in hematopoietic cell transplantation recipients with those in a matched general population sample. Hematopoietic cell transplantation survivors were at greater risk for cardiomyopathy, ...
Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rate in Initial Therapy for Follicular Lymphoma
In a phase II trial reported in the Journal of Clinical Oncology, Illidge et al evaluated radioimmunotherapy with fractionated 90Y-ibritumomab tiuxetan (Zevalin) as initial treatment in patients with mostly advanced follicular lymphoma. The treatment was well tolerated, with manageable...
No Difference in PFS for Temsirolimus vs Sorafenib as Second-Line Therapy After Sunitinib in Metastatic RCC
In the phase III INTORSECT trial reported in the Journal of Clinical Oncology, Hutson et al compared temsirolimus (Torisel) vs sorafenib (Nexavar) as second-line treatment in patients with metastatic renal cell carcinoma after progression on sunitinib (Sutent). There was no significant difference...
No Difference Between Temsirolimus/Bevacizumab vs Interferon Alfa/Bevacizumab in First-Line Therapy for Metastatic Renal Cell Carcinoma
In the phase III INTORACT trial reported in the Journal of Clinical Oncology, Rini et al compared temsirolimus (Torisel)/bevacizumab (Avastin) vs interferon alfa/bevacizumab in first-line treatment of metastatic renal cell carcinoma. There were no significant differences between the two regimens in ...
Study Explores Risk of New Primary Melanomas After Diagnosis of Stage III/IV Melanoma in Patients Not Receiving BRAF Inhibitors
In a study reported in the Journal of Clinical Oncology, Zimmer et al assessed the incidence of spontaneous new primary melanomas in patients with stage III or IV melanoma in order to help clarify risk of BRAF inhibitor–related new melanomas. They found that patients not receiving BRAF...
Preoperative MRI Assessment of Circumferential Resection Margin Predicts Survival and Local Recurrence in Rectal Cancer
In a study reported in the Journal of Clinical Oncology, Taylor et al evaluated the ability of preoperative high-resolution magnetic resonance imaging (MRI) assessment of circumferential resection margin to predict outcome in patients with rectal cancer. They found that MRI assessment was...
Nurse Navigators Improve Patient-Reported Quality of Care in Early Cancer Care
In a study reported in the Journal of Clinical Oncology, Wagner et al assessed whether a nurse navigator intervention improved quality of life or patient experience with care in patients who recently received a diagnosis of breast, colorectal, or lung cancer. Although no differences in...
ASCO Endorses Cancer Care Ontario Guideline for Follow-up in Colorectal Cancer Survivors
ASCO has policy and procedures for endorsing clinical practice guidelines developed by other professional organizations. As reported in the Journal of Clinical Oncology by Meyerhardt et al of the ASCO Clinical Practice Guidelines Committee, ASCO has endorsed the Cancer Care Ontario (CCO)...
12-Gene Recurrence Score Independently Predicts Recurrence in Patients With Stage II/III Colon Cancer
In a study reported in Journal of Clinical Oncology, Greg Yothers, PhD, of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Biostatistical Center and the University of Pittsburgh Graduate School of Public Health, and colleagues assessed performance of the 12-gene colon cancer...
Predictors of Sentinel Lymph Node Metastasis Identified in Thin Melanomas
In a study reported in the Journal of Clinical Oncology, Dale Han, MD, of Moffitt Cancer Center, and colleagues in the Sentinel Lymph Node Working Group attempted to identify factors predictive of sentinel lymph node metastasis in thin melanomas. They found that Breslow thickness ≥ 0.75 mm, ...
STAT3 Activation Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP
In a study reported in the Journal of Clinical Oncology, Xin Huang, PhD, of the National Clinical Research Center of Cancer in Tianjin, and colleagues investigated whether STAT3 activation can identify patients with diffuse large B-cell lymphoma treated with R-CHOP (rituximab [Rituxan] plus...
U.S. Pancreatic Cancer Death Rates Increasing in White Adults, Decreasing in Black Adults
In a study reported in Journal of the National Cancer Institute, Jiemin Ma, PhD, MHS, and colleagues from the American Cancer Society investigated trends in pancreatic cancer death rates in the United States between 1970 and 2009. They found that death rates have been increasing in white men and...
Prognostic Score Predicts Overall Survival in Older Patients With Hodgkin Lymphoma by Second-Line Treatment Strategy
In a study reported in the Journal of Clinical Oncology, Boris Böll, MD, of University Hospital Cologne, and colleagues analyzed second-line treatment and survival in older patients with relapsed/refractory Hodgkin lymphoma in German Hodgkin Study Group first-line studies. Use of a...
Personal History of Prostate Cancer Increases Risk of Melanoma
History of severe acne, which is a surrogate for high androgen activity, has been associated with increased risk of prostate cancer and recent data suggest that severe teenage acne is a risk factor for melanoma. In a study reported in the Journal of Clinical Oncology, Wen-Qing Li, PhD, of the...
Persistent Significant Neurocognitive Impairment in Adult Survivors of Childhood Acute Lymphoblastic Leukemia
In a study reported in the Journal of Clinical Oncology, Kevin R. Krill, PhD, and colleagues from St. Jude Children’s Research Hospital assessed neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia (ALL). They found pervasive significant impairment across...
Statin Use Reduces Cancer-Specific and All-Cause Mortality in Patients With Nonmetastatic Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Oriana Yu, MD, of Jewish General Hospital in Montreal, and colleagues assessed the association of statin use with prostate cancer mortality and all-cause mortality in men with nonmetastatic prostate cancer. They found that postdiagnostic ...
Novel Oncogenetic Classifier Identifies Low- and High-Risk Patients With Adult T-Cell Acute Lymphoblastic Leukemia
The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) recently reported significantly better outcome in T-cell acute lymphoblastic leukemia (ALL) harboring NOTCH1 or FBXW7 (N/F) mutations, although relapse was still observed in one-third of patients with N/F-mutated T-cell ALL. In a ...
Pegfilgrastim Prophylaxis Throughout Chemotherapy Is More Effective in Preventing Febrile Neutropenia in Breast Cancer (and More Costly)
Available data suggest that risk of febrile neutropenia is greatest during the first two cycles of chemotherapy in patients with breast cancer. In a study reported in the Journal of Clinical Oncology, Maureen J. Aarts of Maastricht University Medical Centre in the Netherlands, and colleagues...
Increased Use of Local Excision to Treat Early-Stage Rectal Cancer
Recommended treatment for most stage I rectal cancers is total mesorectal excision. However, local excision is considered an alternative for T1 tumors that are < 30% of the bowel circumference, < 3 cm in size, mobile, well to moderately differentiated, and lack lymphovascular invasion in...
Atorvastatin May Prevent Graft-vs-Host Disease in Allogeneic Stem Cell Transplant Recipients
Because statins exhibit immunomodulatory and anti-inflammatory effects that may ameliorate graft-vs-host disease, they may be a safe strategy following allogeneic hematopoietic cell transplantation. In a phase II study reported in the Journal of Clinical Oncology, Mehdi Hamadani, MD, and colleagues ...
Nivolumab Shows Activity in Ipilimumab-Refractory or -Naive Melanoma in Phase I Trial
In a phase I trial reported in the Journal of Clinical Oncology, Jeffrey S. Weber, MD, of the H. Lee Moffitt Cancer Center and Research Institute, and colleagues assessed the effects of nivolumab—a human immunoglobulin G4-blocking antibody against the T-cell programmed death 1 checkpoint ...
New ASCO Choosing Wisely® List Details Five Cancer Tests and Treatments Routinely Performed Despite Lack of Evidence
The American Society of Clinical Oncology (ASCO) today announced its second “Top Five” list of opportunities to improve the quality and value of cancer care. Published in the Journal of Clinical Oncology (JCO), ASCO’s second Top Five list was released as part of the Choosing...
Problematic Symptoms After Prostate Biopsy Associated With Anxiety
In a study reported in the Journal of Clinical Oncology, Julia Wade, PhD, of Bristol University, United Kingdom, and colleagues assessed the psychological impact of prostate biopsy. They found that postbiopsy symptoms can be associated with increased anxiety, independent of anxiety associated...
Multiple Myeloma Defined by Light Chain Amyloidosis With Plasma Cell or CRAB Criteria
In a study reported in Journal of Clinical Oncology, Taxiarchis V. Kourelis, MD, and colleagues from the Mayo Clinic attempted to define a threshold of bone marrow plasma cell number that could serve to define light chain amyloidosis as light chain amyloidosis with multiple myeloma. They found that ...
Dose-Limiting Late Toxicity Observed After Hypofractionated Dose-Escalated Radiotherapy in NSCLC
In a phase I study reported in Journal of Clinical Oncology, Donald M. Cannon, MD, of University of Wisconsin School of Medicine and Public Health and Mountain States Tumor Institute, and colleagues attempted to identify the maximum tolerated dose of dose-escalated hypofractionated radiation...
Oral Contraceptives Linked to Reduced Risk of Ovarian Cancer and Nonsignificantly Increased Breast Cancer Risk in Women With BRCA1/2 Mutation
In a study reported in the Journal of Clinical Oncology, Patricia G. Moorman, PhD, of Duke University Medical Center, and colleagues evaluated risk of ovarian and breast cancer among oral contraceptive users with BRCA1/2 mutations. The study showed a significantly reduced risk of ovarian...
Association Between Prevalence of Symptoms and Impaired Health-Related Quality of Life in Adult Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, I-Chan Huang, PhD, of University of Florida at Gainesville, and colleagues investigated the association between prevalence of symptoms and health-related quality of life in adult survivors of childhood cancer enrolled in the St. Jude...
Sequential Addition of Gemtuzumab Ozogamicin to Standard Chemotherapy of No Benefit in Older Patients With Newly Diagnosed AML
In a phase III trial (EORTC [European Organisation for Research and Treatment of Cancer]/GIMEMA [Gruppo Italiano Malattie Ematologiche dell’Adulto] consortium AML-17 trial) reported in the Journal of Clinical Oncology, Sergio Amadori, MD, of Tor Vergata University Hospital in Rome, and...
Risk of Congestive Heart Failure Increased With Trastuzumab Use in Older Breast Cancer Patients
Risk and risk factors for congestive heart failure in older breast cancer patients receiving trastuzumab have not been clearly defined. In a study reported in the Journal of Clinical Oncology, Mariana Chavez-MacGregor, MD, of The University of Texas MD Anderson Cancer Center, and colleagues...
Addition of Vintafolide to Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Platinum-Resistant Ovarian Cancer
In a randomized phase II trial reported in the Journal of Clinical Oncology by R. Wendel Naumann, MD, of Carolinas Medical Center in Charlotte, North Carolina, and colleagues, the addition of vintafolide to pegylated liposomal doxorubicin improved progression-free survival in women with...
Long-Term Obesity Is Linked With Poorer Pancreatic Cancer Survival
Although multiple studies have shown that high body mass index (BMI) is associated with an increased risk of developing pancreatic cancer, few studies have evaluated the impact of BMI on survival and none have used prospectively collected data on BMI. Now a large prospective study by Brian M....
Improved Progression-Free but Not Overall Survival With Addition of Maintenance Erlotinib to Bevacizumab After Chemotherapy Plus Bevacizumab in NSCLC
In the phase IIIB ATLAS trial reported in the Journal of Clinical Oncology, Bruce E. Johnson, MD, of Dana-Farber Cancer Institute, and colleagues assessed the addition of maintenance erlotinib (Tarceva) to bevacizumab (Avastin) following chemotherapy plus bevacizumab in first-line treatment of ...
Increased Radiation Dose With Hypofractionated vs Conventional Radiation Therapy Does Not Improve Biochemical/Clinical Failure Rate in Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Alan Pollack, MD, PhD, of University of Miami Miller School of Medicine, and colleagues compared escalated radiation dose using hypofractionated vs conventional fractionation intensity-modulated radiation therapy in men with favorable-...
Increased Risk of Long-Term Cardiovascular Mortality and All-Cause Mortality in Patients With Differentiated Thyroid Carcinoma
In a study reported in the Journal of Clinical Oncology, Esther N. Klein Hesselink, of University Medical Center Groningen in the Netherlands, and colleagues evaluated long-term cardiovascular mortality in patients with differentiated thyroid cancer. They found that risk of cardiovascular and...
RTOG 0525 Subanalysis Finds Worse Outcomes With Dose-Dense vs Standard Adjuvant Temozolomide in Glioblastoma
A phase III trial (Radiation Therapy Oncology Group [RTOG] 0525; N = 833) comparing dose-dense vs standard-dose temozolomide maintenance in newly diagnosed glioblastoma showed no differences in overall survival or progression-free survival between treatments. A substudy of the trial, reported in...
No Benefit of Dose-Dense vs Standard Temozolomide in Newly Diagnosed Glioblastoma, MGMT Methylation Associated With Better Survival
Dose-dense temozolomide results in depletion of O6-methylguanine-DNA methyltransferase (MGMT)—a potential determinant of treatment response—in blood mononuclear cells and possibly in tumors. In a phase III trial (Radiation Therapy Oncology Group [RTOG] 0525) reported in the Journal ...
No Additional Benefit of Venlafaxine or Soy Protein vs Placebo on Hot Flashes in Men With Prostate Cancer
Hot flashes occur in approximately 80% of androgen-deprived men. In a randomized study reported in the Journal of Clinical Oncology by Mara Z. Vitolins, DrPH, MPH, RD, of Wake Forest School of Medicine, and colleagues, neither venlafaxine nor soy protein—both of which have been used to...
Promising Outcomes With R-MPV Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma
In a phase II trial reported in the Journal of Clinical Oncology, Patrick G. Morris, MD, of Memorial Sloan-Kettering Cancer Center, and colleagues assessed the efficacy of rituximab (Rituxan), methotrexate, procarbazine (Matulane), and vincristine (R-MPV) followed by consolidation reduced-dose ...
Outcome Improved in MET-Positive and Worsened in MET-Negative NSCLC With Addition of Onartuzumab to Erlotinib in Phase II Trial
In patients with non–small cell lung cancer (NSCLC), increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to EGFR-targeted treatment. In a phase II study reported in the Journal of Clinical Oncology, David R. Spigel, MD, of Sarah...
